FY2027 EPS Estimates for ImmunityBio Raised by HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at HC Wainwright upped their FY2027 earnings estimates for ImmunityBio in a research report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of $0.05 for the year, up from their previous forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s FY2028 earnings at $0.33 EPS and FY2029 earnings at $0.55 EPS.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million.

Several other brokerages have also commented on IBRX. Piper Sandler upped their price target on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a report on Tuesday, January 20th. Jefferies Financial Group boosted their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, BTIG Research raised their price target on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $6.15 on Thursday. The stock’s fifty day moving average is $2.98 and its two-hundred day moving average is $2.65. The firm has a market capitalization of $6.06 billion, a P/E ratio of -15.00 and a beta of 0.03. ImmunityBio has a fifty-two week low of $1.83 and a fifty-two week high of $8.28.

Institutional Trading of ImmunityBio

Several hedge funds have recently modified their holdings of IBRX. AQR Capital Management LLC boosted its position in shares of ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after purchasing an additional 29,297 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in ImmunityBio in the second quarter valued at about $43,000. Vigilare Wealth Management purchased a new stake in shares of ImmunityBio during the 2nd quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ImmunityBio by 39.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,095 shares of the company’s stock worth $90,000 after acquiring an additional 9,663 shares during the period. Finally, Grimes & Company Inc. increased its stake in ImmunityBio by 484.4% in the 2nd quarter. Grimes & Company Inc. now owns 58,436 shares of the company’s stock valued at $154,000 after purchasing an additional 48,436 shares in the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 151,967 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the sale, the director owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christobel Selecky sold 50,000 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $5.00, for a total value of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 226,967 shares of company stock worth $1,531,912 in the last 90 days. 69.48% of the stock is currently owned by company insiders.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.